logo
Plus   Neg
Share
Email

VF Corp. Issues Q1 Guidance - Quick Facts

VF Corp. (VFC) said it expects first quarter revenues to be down slightly more than 50%. Full-year fiscal 2021 free cash flow is expected to exceed $600 million.

For the fourth quarter, on an adjusted basis, earnings per share decreased 70 percent (down 69 percent in constant dollars) to $0.10. On average, 18 analysts polled by Thomson Reuters expected the company to report profit per share of $0.13, for the quarter. Analysts' estimates typically exclude special items.

Fourth quarter revenue decreased 11 percent (down 10 percent in constant dollars) to $2.1 billion driven by lower consumer demand as a result of the COVID-19 outbreak. Analysts expected revenue of $2.31 billion for the quarter.

VF has approximately $3 billion of cash on hand in addition to approximately $2.2 billion available under its revolving credit facility. Currently, all of VF's retail stores in the APAC region, including Mainland China, have re-opened.

On May 12, 2020, VF's Board of Directors declared a quarterly dividend of $0.48 per share. The dividend will be payable on June 22, 2020, to shareholders of record on June 10, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT